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Ann A. Jakubowski,1 Trudy N. Small,2 Nancy A. Kernan,2 Hugo Castro-Malaspina,1
Nancy Collins,3 Guenther Koehne,1 Katharine C. Hsu,1
Miguel A. Perales,1 Genovefa Papanicolaou,4 Marcel R. M. van den Brink,1
Richard J. O’Reilly,2 James W. Young,1 Esperanza B. Papadopoulos1We report a prospective phase II clinical trial in 35 adult patients (median age 40.5 years) with hematologic
malignancies who received T cell–depleted, hematopoietic stem cell transplants from HLA-compatible,
unrelated donors. The cytoreductive regimen consisted of hyperfractionated total-body irradiation, thiotepa,
and fludarabine. The preferred graft source was granulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (PBSC). PBSC were CD341 selected, followed by sheep erythrocyte rosetting
to deplete residual T cells. Anti-thymocyte globulin provided graft rejection prophylaxis. No additional
graft-versus-host disease (GVHD) prophylaxis was planned. Estimated disease-free survival at 4 years is
56.8% for the entire group and 75% in patients with standard-risk disease. The cumulative incidence of relapse
is 6%.AcuteGVHDgrade II-III developed in 9% and chronicGVHD in29%of patients. Fatal infectionsoccurred
in 5of 35 (14%)patients. Therewas 1 late graft failure. This studydemonstrates durable engraftmentwith a low
overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years.
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malignanciesINTRODUCTION
Several studies have demonstrated the efficacy of T
cell–depleted (TCD) allogeneic bone marrow (BM)
[1-3] and TCD peripheral blood stem cell transplants
(PBSCT) [4,5] from matched related donors (MRD)
in patients with hematologic malignancies. In these
reports, reduction in the incidence and severity of
acute and chronic graft-versus-host disease (aGVHD,
cGVHD) compared with T cell–replete transplanta-
tion, has not compromised the antitumor effect of the
allograft. Furthermore, a 5-year follow-up of patients1Adult Allogeneic Bone Marrow Transplant Service,
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6/j.bbmt.2011.01.005receiving TCD sibling transplants reported excellent
performance status and quality of life [6]. In contrast,
TCD transplants from unrelated donors have been
less well studied [3,7,8].
Although the addition of anti-thymocyte globulin
(ATG) addressed an early unacceptable rate of
immune-mediated graft rejection and provided addi-
tional GVHD prophylaxis beyond that of TCD alone
[9,10], it has resulted in delayed immune recovery [11].
We reported recently that conditioning with hyperfrac-
tionated total-body irradiation (HFTBI), thiotepa, and
fludarabine in TCD PBSCT using MRD eliminated
the need for ATG without increasing graft rejections.
Furthermore, immune reconstitution improved with
a reduction in opportunistic infections (OI) [5].
To extend curative transplantation options to pa-
tients without anMRDand to an older population at in-
creased risk of GVHD, we utilized this regimen for
matched or mismatched unrelated donor transplants.
Only 2 doses of ATG were administered, and TCD
wasperformedby automatedCD341 stemcell selection
followedby rosettingwith sheep red blood cells (sRBC).
Wereport the results of a trial in 35patients,which eval-
uated the impact of this approach on transplant-related
morbidity and mortality in patients with hematologic1335
1336 Biol Blood Marrow Transplant 17:1335-1342, 2011A. A. Jakubowski et al.malignancies. Secondary endpoints were to estimate
disease-free survival (DFS) and overall survival (OS).
We sought also to determine whether patients could
achieve consistent engraftment with durable relapse-
free survival (RFS) and whether T cell reconstitution
could be improved with a low incidence of OIs.MATERIALS AND METHODS
Patient Characteristics
Thirty-five adult patients with a variety of malig-
nant hematologic diseases and treatment backgrounds
were enrolled on this Memorial Sloan-Kettering
Cancer Center (MSKCC) Institutional Review and
Privacy Board–approved, phase II trial from July 1,
2001, to December 31, 2005, after obtaining informed
consent. Analysis was performed as of December 31,
2008, after which there were no censored events.
Eligibility included low level of disease or remission,
availability of$7/10 HLA-matched unrelated donors,
Karnofsky performance status (KPS) $70, no active
infection or extramedullary disease, and satisfactory
organ function as previously described [5].
Only those patients with intermediate- or high-risk
acutemyelogenous leukemia (AML)basedoncytogenet-
ics [12], and with acute lymphoblastic leukemia (ALL)
high-risk cytogenetics (generally t(9;22) with p190 bcr-
abl or t(4;11]) underwent transplantation in first com-
plete remission (CR1). Disease status at transplantation
determined standard- or poor-risk classification: AML-
CR1, -CR2, ALL-CR1, or CML-first chronic phase
were standard risk; all others were poor risk [5]. HLA
matching for -A, -B, -C, -DRB1, and -DQB1 lociwas es-
tablished using DNA sequence–specific oligonucleotide
probes.Donors were identified and recruited via theNa-
tional Marrow Donor Program (NMDP) registry.Preparative Regimen and Graft
The cytoreduction consisted of HFTBI followed
by thiotepa, ATG, and fludarabine [5]. HFTBI was
administered in 11 fractions of 125 cGy over 4 days,
to a total dose of 1375 cGy. All patients had protective
lung shielding after an initial 800 cGy, and overlying
ribs received an additional 600 cGy boost. Male pa-
tients with acute leukemia or lymphoma received an
additional 400 cGy testicular boost in a single fraction.
After completion ofHFTBI, thiotepa 5mg/kg/day was
administered over 4 hours on each of 2 consecutive
days, with no adjustment for weight. Fludarabine
25 mg/m2/day was administered over 30 minutes for
5 days, beginning on the first day of thiotepa. Patients
received 2 doses of equine (60 mg/kg total) or rabbit
(5 mg/kg total) ATG divided over the same 2 days as
the thiotepa. The source of rabbit ATG was Sangstat
(Fremont, California) until 2003 and thereafter Gen-
zyme (Cambridge, Massachusetts).Twenty-nine donors underwent G-CSF mobiliza-
tion of PBSC according to NMDP guidelines.
Targeted cell dose was 109 MNC/kg (3  106
CD341/kg) of recipientweight.CD341 cells were pos-
itively selected using the ISOLEX 300i Magnetic Cell
Selection System (BaxterHealthcareCorp.,NewProv-
idence, New Jersey), followed by sRBC-rosette deple-
tion of T cells [5]. This achieved an approximately 5
log10 depletion of CD3
1 cells [13]. Six donors elected
BM harvesting with TCD accomplished by sequential
soybean lectin agglutination and sRBC-rosette deple-
tion (SBA-E-) [14]. Fresh grafts were infused through
a central venous catheter 24 to 48 hours after complet-
ing fludarabine.
GVHD Evaluation and Management
GVHD was diagnosed clinically and confirmed by
biopsy whenever possible. Patients, who engrafted and
survived.30 days, were evaluable for aGVHD, unless
it had already been diagnosed before a terminal event.
Scoring was based on Center for International Blood
and Marrow Transplant Research (CIBMTR) criteria
[15]. Patients surviving .100 days were evaluable for
chronicGVHDusing the Sullivan scoring criteria [16].
Supportive Care
Patients were managed clinically according to
MSKCC standard guidelines [5], including infection
prophylaxis for Pneumocystis carinii, Herpes viruses,
and fungus. Patients who were seropositive for Toxo-
plasma gondii or whose donors were seropositive, also
received atovaquone prophylaxis after transplantation.
Patients who were cytomegalovirus (CMV) negative
received seronegative blood products regardless of
the donor’s serologic status. If the patient or donor
was seropositive, CMV-specific prophylaxis was ad-
ministered beginning when the absolute neutrophil
count (ANC) was self-sustaining .2000 cells/mL and
continuing through day1100. This consisted of main-
tenance dosing of valganciclovir, as peripheral blood
counts tolerated, and maintenance foscarnet dosing if
they did not. Monitoring of CMV reactivation by
CMV pp65 antigenemia assay of peripheral blood
was performed regularly when either the patient or do-
nor was CMV seropositive, generally once per week
during the first 100 days. Epstein-Barr virus (EBV)
was monitored similarly by qualitative polymerase
chain reaction (PCR) until 2003 and thereafter by
real-time PCR of the BNRF1-p143 locus (Roche
Inc., Indianapolis, IN) [17].
Prophylactic antibacterial agents were not used
until 2005. At that time, the practice of administering
vancomycin prophylaxis against Streptococcus viridans at
the development of neutropenia or no later than day
22 was initiated. This practice affected 4 patients on
this study. Finally patients received granulocyte
Table 1. Pretransplant Demographics and Disease Status
Total # Pts 35
KPS—range (median) 70-100 (90)
M:F 21-14
Age—range (median) 18.2-62.8 (40.5) years
Diseases
AML CR1 6
Intermediate risk* 3
High risk 3
AML CR2 10 (1 after MDS)
ALL CR1 3
ALL CR2 7
ALL CR $3 3
AL (other) 2 (1 CR, 1 extramedullary
relapse)
CML CP1 1
MDS 2 (1 RA- Intermed
IPSS, I RAEB)
T-PLL 1
Donors
Matched: Mismatched 17:18
M/ F 9
M/ M 12
F/ M 7
F/ F 7
Age—range (median) 19-54 (36) years
Grafts
PBSC 29
BM 6
HLA disparity for MM transplants 18
9/10 1 antigen A;C 2;2
1 allele A;C;DQ 2;1;1
8/10 2 antigen A,C;A,DQ;B,C 1;1;2
1 antigen + 1 allele A,DQ;A,C; 1;2
C,DR;DR,DQ 1;1
7/10 1 antigen + 2 alleles
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after day 17, if clinically indicated.
Engraftment, Donor Chimerism, and Immune
Reconstitution
Standard engraftment criteria were used: i.e., ANC
$500/mL without G-CSF support and platelets
$20,000/mL without transfusion for $3 consecutive
days. BM aspirates were monitored for disease status
and donor chimerism.
Immunophenotyping and T cell–proliferative re-
sponses to phytohemagglutinin (PHA) mitogen were
evaluated every 3 to 6 months until normal [18].
Life-threatening infections were defined as organ-
localized infections because of viral, fungal, and/or
parasitic pathogens as previously described [5].
Biostatistics
DFS, defined as the interval from transplantation to
death, hematologic or clinical relapse, or last follow-
up, was estimated using the method of Kaplan-Meier.
Estimates of the probability of relapse and nonrelapse
mortality (NRM) were calculated with the cumulative
incidence function [19]. Wilcoxon rank sum test was
used to compare immune reconstitution results be-
tween groups of patients. Primary cause of death was
determined by previously published criteria [20].A,C,DQ 1
AML indicates acute myelogenous leukemia; ALL, acute lymphocytic
leukemia; AL, acute leukemia multilineage; CML, chronic myelogenous
leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia;
RAEB-IT, refractory anemia with excess blasts in transformation;
T-PLL, T cell prolymphocytic leukemia; CP, chronic phase; CR, complete
remission; KPS, Karnofsky performance status. * by cytogenetics.RESULTS
Patient and Donor Characteristics
Table 1 details patient and donor characteristics.
Median patient age was 40.5 years, with 10 patients
$50 years. Eighteen patients were classified as stan-
dard risk and 17 were poor risk. Two BMgrafts arrived
in poor condition and could only be processed with
soybean agglutination. This necessitated short-term
calcineurin inhibitor therapy with these grafts, which
contained 2.3 and 2.6 106 CD31/kg (1-2 logs higher
than the CD31 dose in other grafts). Eighteen donors
were HLA disparate at 1-3 of 10 loci (Table 1). Four
patients received 2 doses of rabbit ATG by physician
choice. Two patients received 1 dose of rabbit and 1
dose of horse ATG because of a reaction during the
first dose.
Engraftment and Donor Chimerism
All 34 evaluable patients engrafted neutrophils.
One infectious death on day 15 was inevaluable.
CD341 andCD31 cell dose engraftment data are sum-
marized in Table 2. The median CD341 dose was
within the range targeted by the protocol (3  106
CD341 cells/kg). Ten grafts contained less than the
targeted dose; half were the TCD BMs. The patient
who received the lowest CD341 dose (TCD BM, 0.8
 106/kg) exhibited delayed engraftment and requireda BM boost. Three of 34 evaluable patients died before
achieving platelets .20,000/mL.
One patient with ALL CR2 rejected a 9/10 HLA
matched PBSCT. Day 130 evaluation revealed only
55% donor chimerism, with multiple new chromo-
somal abnormalities. This patient died from complica-
tions following a second transplant. Thirty of the 34
evaluable patients achieved full donor chimerism in
BM by day 1100. Four were not evaluated.
At 1 year, 21 of 26 evaluable patients were studied:
19 had full donor chimerism, 2 were $80% donor.
One improved with an infusion of donor lymphocytes
(DLI), the other spontaneously. Within 24 months
posttransplantation (the last evaluation required by
protocol), 21 of 25 evaluable patients studied demon-
strated $95% donor chimerism. The 1 patient with
an HLA-matched donor who received low-dose DLI
for mixed chimerism did not develop GVHD.GVHD
The median CD31 dose for the 35 patients was
1.52  103 CD31 cells/kg, far below the threshold of
Table 2. Outcome Data
Median Follow-Up (range) 52 (37-83.1) mns
Engraftment 34 (evaluable)
Median transplant dose CD34+  106/kg (range) 3.9 (0.80-11.57)
Median transplant dose CD3+  103/kg (range) 1.52 (0-259)
Patients engrafting neutrophils 34
Median days to ANC $500/mL (range) 12 (9-19) days
Patients engrafting platelets 32
Median days to platelets $20,000/mL (range) 19 (14-108) days
Posttransplant EBV-LPD 3
GVHD
Acute (overall grade) 2/34 (1M:1MM)
II 1 (1M)
IV 1 (1MM)
Chronic 8/28 (5M:3MM)
Limited 5 (2M:3MM)
Extensive 3 (3M)
Relapses 2
ABL > CR2 (w/extramedullary disease) 1
ALL CR2 1
Deaths 14
Matched:mismatched 6:8
Causes of death
Infection 6
Bacterial 2
Viral (adenovirus) 2
Toxo/fungal 1/1
EBV-LPD and secondary complications 1
Post-second transplant complications 1
GVHD and secondary complications 3
Late GF 1
IP 1
VOD 1
100-day NRM 20% (2M:5MM)
Bacterial 1
Viral (adenovirus) 2
Toxo:bacterial 1:2
VOD 1
Late GF 1
Mns indicates months; mL, microliter; EBV-LPD, Epstein-Barr virus-
lymphoproliferative disease; M, matched; MM, mismatched; ABL, acute
biphenotypic leukemia; ALL, acute lymphocytic leukemia; CR, complete
remission; GVHD, graft-versus-host disease; toxo, toxoplasmosis; GF,
graft failure; IP, interstitial pneumonitis; VOD, veno-oclusive disease.
Figure 1. Kaplan-Meier estimates of the probability of disease-free
survival at 4 years based on the status of disease.
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mined by limiting dilution outgrowth using TCD BM
from HLA-identical siblings [21]. Thirty-four of the
35 patients were evaluable for aGVHD (Table 2).
The incidence of grade II-IV was 5.8%. One of these
patients, with an HLA-matched donor, received the
highest T cell dose (22.8  103 CD31/kg) among the
TCD PBSC grafts. The second patient received a mis-
matched BM allograft containing 15.7 103 CD31/kg.
Their grade IV lower gastrointestinal (GI) GVHD
responded quickly to steroid therapy.
Twenty-eight patients were evaluable for cGVHD.
Five developed limited and 3 extensive GVHD. Three
previously had aGVHD. Incidence was similar in those
with matched (18%) versus mismatched (11%) donors
(7-8/10 matches). One patient required calcineurin
inhibitor prophylaxis because of the higher residual
T cell content in the graft. Three patients died from
complications of cGVHD. The overall incidence of
cGVHD was 29%, with only 11% extensive.DFS and Relapse
Patients had a variety of diagnoses and treatment
histories, and were almost equally divided between
‘‘standard’’ (n 5 18) and ‘‘poor’’ (n 5 17) risk disease
(Table 1). Estimated probabilities of DFS and OS at
4 years for the entire group were 57% and 59%,
respectively (median follow-up 52months). Figure 1 il-
lustrates the probability of DFS at 4 years for patients
following standard risk—75%, compared to poor-risk
transplants—41% (P 5 .057). Figure 2 illustrates OS.
DFS andOS for patients age$40 years were not signif-
icantly different from that for younger patients. Ten
patients were $50 years, 4 in the poor- and 6 in the
standard-risk transplant groups. Three of the 10 died
from early infections (adenovirus, toxoplasma, and
vancomycin-resistant Enterococcus [VRE] sepsis), 1
each from cGVHD, interstitial pneumonitis, and an
unrelated gastrointestinal malignancy (at 72 months).
No significant difference was observed for matched
versus mismatched transplants in either DFS, or OS;
however, the number of patients is limited.
Cumulative incidence of relapse at 4 years is only
6% (Figure 3A). Both patients who relapsed had
poor-risk disease: 1 with acute biphenotypic leukemia,
who developed leukemia cutis during conditioning,
relapsed at 38 months; the second with ALL CR2 re-
lapsed at 31 months Both received second (T-replete)
transplants, and 1 survives in remission at 30 months.
Of the 18 patients who were HLA-mismatched,
4 donor-recipient pairs exhibited killer cell
immunoglobulin-like receptor (KIR) ligand incompat-
ibility. Of these, 3 pairs hadKIR ligand incompatibility
in a host-versus-graft vector, and only 1 pair had KIR
ligand incompatibility in a graft-versus-host vector.
For this 1 pair, however, donor KIR genotyping re-
vealed lack of the relevant inhibitory KIR responsible
for sensing the class I ligand lacking in the recipient.
All of the remaining HLA-mismatched patients were
KIR ligand compatible.
Figure 2. Kaplan-Meier estimates of the probability of overall survival
at 4 years for all patients.
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Disease
Three patients (8.5%) developed biopsy-confirmed
EBV-lymphoproliferative disease (LPD), at 3, 6, and 7
months. All recovered with therapy (1 rituximab, 1 ritux-
imab1DLI, 1 EBV-specific cytotoxic T cells). The pa-
tient who received DLI from their C allele–mismatched
donor at 3 months eventually died from complications
of GVHD. Death was attributed to complications of
EBV-LPD.Causes of Death
Fourteen (40%) of the 35 patients died by the
4-year follow-up. Five had matched and 9 had mis-
matched donors. Causes of death are summarized in
Table 2. Cause-specific probability of NRM, adjusted
for the competing risk of relapse, is 20% at 100 days,
and 29% at 1 year (Figure 3B).Figure 3. Cause-specific analysis of relapse and mortality. A, Cause-
specific probability of relapse, adjusting for completing risks of treatment
failure by nonrelapse causes. B, Cause-specific probability of death,
adjusting for the competing risk of relapse.Immune Reconstitution and Infections
The median time to recovery of normal numbers
of circulating CD81 T cells and to .200 CD41 T
cells/mL was 4 to 6 and 6 to 9 months, respectively
(Figure 4). Only 4 patients who received steroids
within the first 12 months had persistently low
CD41 cells (\100 cells/mL) throughout the first 2
years. By 12 to 18 months, CD41CD45RA1 cells
recovered in 50% of patients, and the majority of pa-
tients’ PHA T cell–proliferative responses reached
the lower limit of normal (LLN). All patients devel-
oped normal numbers of CD561CD161 NK cells by
2 months after transplantation (data not shown).
The 30-day absolute lymphocyte count (ALC),
reported to predict outcomes in TCD HLA-matched
sibling transplantpatientswith acute leukemiaor chronic
myeloid leukemia (CML) [22], was analyzed for the en-
tire group. Median ALC at 30 days was 474 cells/mL.
There was no difference in the incidence of death or re-
lapse for patients with an ALC at 30 days above or below
this median (data not shown). Thirty patients, who
achieved a circulating lymphocyte count of 500 cells/
mL, did so at amedian time (range) of 19.5 (14-223) days.
Eleven of 35 patients developed a life-threatening
OI because of adenovirus (n5 5), EBV (n5 3), fungus
(n 5 1), toxoplasmosis (n 5 1), or Nocardia (n 5 1).
Three of 16 patients at risk for CMV reactivation re-
quired treatment: 1 CMV colitis and 2 viremias. Three
additional patients experienced nonfatal RSV infec-
tions and 1 atypical mycobacterium infection Five
died of their OIs: 2 adenovirus, 1 each toxoplasmosis,
EBV, and fungus. Four of these patients had received
mismatched grafts.DISCUSSION
This trial addresses the use of myeloablative TCD
transplantation from HLA-matched and -mismatched
unrelated donors with current day technology and prac-
tices. The goals were to provide effective therapy with
a low rate of relapse, to facilitate T cell recovery, and
to decrease regimen-related toxicity. Despite the high-
risk nature of many of the transplants andmodifications
to the regimens, the study demonstrated promising
results: only a 6%cumulative incidenceof relapse, excel-
lent engraftment, and low rates of GVHD. Confound-
ing contributors to GVHD were incomplete TCD
and use of DLI. Death because of infection occurred
in 20% of patients, most of them in the peritransplant
setting or in association with GVHD therapy.
Limited reports of unrelated TCD BM or PBSC
grafts following myeloablation have been published
[7,23-26]. Most studies utilized partial TCD together
with immune suppressive medications [25] posttrans-
plant. They reported slower immune recovery, a higher
incidence of infectious complications [18,27,28] and
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Figure 4. T cell recovery. Shown are the 10-50-90th percentiles of
CD41 and CD45RA1 cells per microliter obtained over 24 months
for 26 patients following peripheral blood stem cell transplantation on
this study.
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transplantation [29-31]. Use of ATG has also been
associated with similar complications [1,32]. The
majority of studies, including the largest trial [33], de-
scribed patients treated in the 1980s to 2000 using BM
allografts. The current study addresses an older patient
population, but incorporates improved supportive
care, high-resolution HLA typing, improved TCD
technology, and PBSC graft source.
Studies suggest that higher doses of CD341 cells fa-
cilitate engraftment and immune reconstitution [34-36].
In this study, TCD PBSCs grafts had 5.75  106/kg
median CD341 cell doses, similar to T cell replete
PBSC [37], and much higher than 1.2  106/kg for
TCD BM grafts (historical, unpublished results). Log
10 depletion of CD31 in PBSC was 5.5 compared
with 2.5 to 3 for BM. The level of TCD in this study
is approximately 1/2 log greater than that achieved
with the currently available CliniMACS device [38].
Median age of the patients was.10 years older than
our earlier reports and similar to our recent study of
TCD matched, related PBSC transplants [1,2,5].
Distribution of diseases was representative of older
patients and included many treated at advanced stages.
Infectious complications reflect current day pathogens
but notably, did not include streptococcal bacteremias,
which were observed with this regimen previously [5].
Early initiation of antibiotics, for fevers during condi-
tioning, may have avoided this complication.
This trial evaluated changes in the regimen and
graft. Despite reducing the intensity of the condition-
ing, the OS andDFS for the 17 ‘‘standard’’-risk patients
was excellent, .70% and comparable to our previous
results [5] and those reported by others. The Kaplan-
Meier survival curve for this group did not change after
the eighthmonth. The OS andDFS for the ‘‘poor’’-risk
transplant group was 47% and 41%, respectively, again
similar to those with T cell–replete grafts, but with less
GVHD. Median follow-up for this trial was .4 years,
encompassing the only 2 relapses. The very low inci-
dence of relapse argues against a loss of graft-versus-tumor effect with TCD. Deaths on this trial generally
occurred within the first 6 to 8 months and were pre-
dominantly infection-related.
The low relapse rate in the setting of a TCD
allograft invokes the possibility that NK cells are the
primary mediator of the graft-versus-tumor effect.
Classic NK alloreactivity because of KIR-mediated
recognition of ‘‘missing self’’ occurs when major histo-
compatibility complex (MHC) class IKIR ligands pres-
ent in donor are lacking in the transplant recipient.
Only 4 of the 18 HLA-mismatched donor-recipient
pairs exhibited KIR ligand incompatibility, and only
1 of these pairs had KIR ligand incompatibility in
a graft-versus-host vector. For this 1 pair, however,
donor KIR genotyping revealed lack of the relevant in-
hibitory KIR responsible for sensing the class I ligand
lacking in the recipient; and thus, no NK alloreactivity
because of recognition ofmissing selfwould occur.Do-
nor NK alloreactivity because of missing self-MHC,
therefore, could not account for the low relapse rate
among these patients.
NK alloreactivity because of ‘‘missing ligand,’’
which we have previously described [39], can occur
when the patient is lacking any class I ligand for donor
inhibitory KIR, irrespective of whether the ligand is
present in the donor. This receptor-ligand mismatch
occurred in 22 of the 35 pairs. Because the event of
relapse is low in this small cohort, however, we cannot
conclude that NK alloreactivity because of missing li-
gand is responsible for protection from relapse. A
larger cohort would be necessary to confirm this.
A goal of the current studywas to reduce the dosing
of ATG and potentially improve immune recovery
without increasing the incidence of graft rejection or
GVHD. Based on previously identified predictors of
graft rejection using TCD BM grafts [9,40], more
than half the patients were at increased risk.
However, only 1 HLA-mismatched graft recipient, in
the poor-risk group, experienced late graft failure.
Enhanced immunosuppression provided by fludara-
bine coupled with the higher CD341 dose achieved
with PBSCs likely contributed to the high rate of dura-
ble engraftment. These results support further reduc-
tion in ATG dosing in future trials.
The TCD PBSC contained .1 log10 lower con-
centration of T cells compared with TCD BM grafts
(median 1.2 versus 42.5  103/kg) [14] and a 4 log10
lower concentration than T cell–replete PBSC grafts
with similar CD341 numbers [37]. However, the inci-
dence and severity of GVHD in this study, is higher
than that previously reported for our TCD BM and
PBSC with matched related donors [2,5], and for
HLA haplotype–disparate related donors reported by
Aversa et al. [41]. Factors contributing to the GVHD
might include: (1) additional allogeneic disparities in
unrelated andmismatched donors, (2) qualitatively dif-
ferent T cell and NK populations in TCD PBSC
Biol Blood Marrow Transplant 17:1335-1342, 2011 1341TCD Unrelated Hematopoietic Stem Cell Transplantationversus TCD BM, and (3) the relatively low dose of
ATG employed.
The goal of utilizing lower-dose ATG was to im-
prove T cell recovery and potentially reduce life-
threatening OIs. Recovery of CD4 counts to $200
and normalization of CD8 T cells were similar for
the TCD PBSC (6-9 months), compared with unre-
lated TCDBM (12-18 months) [18]. CD41CD45RA1
cell recovery was also faster than for unrelated TCD
BM. Thus, despite including ATG, time to recovery
of CD41 and CD41CD45RA1 cell counts in this trial
was similar to that for recipients of related TCDPBSC
using identical cytoreduction but without ATG [5].
Similarly, patients’ PHA response normalized faster
on this trial than in recipients of TCD unrelated BM,
who had a PHA response \25% LLN for the first
year versus the median PHA response in this study of
60% LLN at 12 months, and normal by 18 months.
Keever-Taylor et al. [42] recently published the results
of lymphoid recovery in patients transplanted on the
National Heart, Lung and Blood Institute randomized
TCD versus a T cell–replete unrelated BM trial, which
included posttransplant immunosuppression. Despite
the older age of the current study patients, recovery
of CD41 cells was similar and ofCD41CD45RA1 cells
more rapid compared to that reported by Keever-
Taylor et al. (median age 31.2 years).
Infection as the primary cause of death occurred in
17%. This is lower than the 29% and 30% incidence
of fatal infection reported byWagner et al. [43] in recip-
ients ofT cell–repleteorTCDunrelated stemcell trans-
plants who received immunosuppressives for GVHD
prophylaxis. Furthermore, the higher incidence of
deaths from CMV and fungus reported by van Burik
et al. [44] in TCD unrelated transplant recipients who
also received posttransplant GVHD prophylaxis was
not observed in this study. No patient died of CMVdis-
ease, and only 1died of a fungal infection.
This study supports the use of TCD PBSC trans-
plantation from both matched and mismatched unre-
lated donors in appropriately selected adult patients,
especially those at increased risk of GVHD. Ac-
knowledging the limited numbers of patients, the
median survivals compare favorably with those re-
ported by the NMDP for each disease group [45].
The risk of relapse was remarkably low, with a median
follow-up of .4 years. The character of complica-
tions and death was similar to that observed with
T-replete transplantation, but with a lower incidence
and severity of GVHD. Adequately TCD PBSC
from unrelated donors precludes the need for post-
transplant GVHD prophylaxis, allowing more rapid
recovery of functional immunity that reduces the
risk of lethal opportunistic infections. It provides an
alternative form of transplantation for patients with-
out sibling donors including those who are older
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